AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 82 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $653,968 | -24.4% | 63,492 | +9.0% | 0.00% | – |
| Q2 2023 | $864,475 | +2601.5% | 58,253 | +328.3% | 0.00% | – |
| Q2 2022 | $32,000 | -80.5% | 13,600 | -41.9% | 0.00% | – |
| Q1 2022 | $164,000 | -13.7% | 23,400 | -14.0% | 0.00% | – |
| Q2 2021 | $190,000 | -48.1% | 27,200 | -34.1% | 0.00% | – |
| Q1 2021 | $366,000 | +8.0% | 41,274 | -18.4% | 0.00% | – |
| Q4 2020 | $339,000 | +229.1% | 50,601 | +151.7% | 0.00% | – |
| Q3 2020 | $103,000 | -71.0% | 20,100 | -55.0% | 0.00% | -100.0% |
| Q2 2020 | $355,000 | -73.6% | 44,700 | -71.0% | 0.00% | -75.0% |
| Q1 2020 | $1,345,000 | +301.5% | 154,261 | +96.1% | 0.00% | +300.0% |
| Q3 2019 | $335,000 | +228.4% | 78,645 | +121.1% | 0.00% | – |
| Q2 2019 | $102,000 | -47.7% | 35,572 | +32.7% | 0.00% | – |
| Q2 2018 | $195,000 | 0.0% | 26,800 | 0.0% | 0.00% | – |
| Q1 2018 | $195,000 | +72.6% | 26,800 | +94.6% | 0.00% | – |
| Q4 2017 | $113,000 | – | 13,774 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
| Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
| JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
| ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
| FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
| KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
| Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
| Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
| HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |